Nuformix Share Discussion Threads

[amaretto1] 26/11/2021 11:00

My bet is on a past employee !!

[amaretto1] 26/11/2021 10:40

Agree with that .....Probably the pirate who wants the company back on the cheap !!

[soupdragon55] 25/11/2021 22:07

It'll happen amaretto, it'll just take a bit of time. People tend to react more when they can see numbers attached. Most people here will never research enough to understand what NFX have at the moment, they just wait for a contract rns to spell it out for them.

[amaretto1] 25/11/2021 18:50

More u read the RNS Bewildering how this has not been taken seriously by the market I'm not sure they understand at all. It's a 1 billion pound drug Coming off licence in the very near future......Nebuliser format self administering.I'm definitely in for a considerable amount more.

[sentiment riles] 25/11/2021 13:07

Its not magic. A friendly maker helps too lol but not always required

Just need to be sure not them doing the selling of course. Maybe they part do it to drive sentiment to lows sometimes

But on aggregate makes sense for them at the final whistle

Day to day irrelevant when you have the blueprint

[sentiment riles] 25/11/2021 13:03

Mostly yes . Only then

[for fx sake] 25/11/2021 12:49

OK, so why did almost the entire share capital volume of the company change hands immediately after the placing?Doesn't sound like many held on to me and I haven't seen much in the way of accumulation since.In your vast experience, does the price normally go from 3p to 1.7p when sustained accumulation is going on?

[david gruen] 25/11/2021 11:52

"The real accumulation has not started."

Once your knowledge surpasses the foundational level you will understand that the accumulation has been ongoing for over 18 months. Of course the trades are retail, of course we're rising on relatively low volume. Why? because the larger players are not selling what they've spent 18 months accumulating. (they are no longer trying to keep the price in the downtrend).

[for fx sake] 25/11/2021 11:45

The largest trade we have seen is below £15k. These are retail only trades. Traders taking a punt for their 2%. The real accumulation has not started.A broker should have institutional clients on standby for a company with this kind of potential who will be ready to pile in when the time is right...and their trades might be a little bigger than what we're seeing so far today.

[sentiment riles] 25/11/2021 11:32

No signs of accumulation? Disagree . Unless you mean just TR1s

[for fx sake] 25/11/2021 11:19

Allenby's clients should have been briefed on what to wait for in order to accumulate here.We hzve have positive NFX004 and an Oxilio deal for NXP001. I woukd have thought that this RNS would have been a key trigger. No signs of big accumulation yet though. What are they waiting for, perhaps clarification on the replacement CEO?

[david gruen] 25/11/2021 11:07

This is only the beginning.

Do the opposite of what Jaforsadi says and you won't go far wrong.

[sentiment riles] 25/11/2021 10:46

Only the beginning

[inipvestor] 25/11/2021 10:02

Good news at last? I would sell and forget this dawg.

[jaforsadi] 25/11/2021 09:41

More impaled holders

[for fx sake] 25/11/2021 08:42

I have been fairly critical of AB mainly due to the effect on share price since she came on board and the fact she resigned when she did.I reserve my final judgement until I see how this data affects the valuation. The broker she hired told us that pre-clinical NXP002 with a phase 1 ready package should value the company at 9p per share. The release of this RNS tells me that there shouldn't be much standing in the way of that.If this is indeed the turning point we have all been waiting for then I was wrong and I thank her and the rest of them team and wish her all the best for the future.

[for fx sake] 25/11/2021 08:36

I don't know exactly what is different between the interview and this RNS. I do know that Riddell said in the interview that the data was good but they didn't yet know how good. Maybe that has been confirmed in the last week. We're still due the durability report in Jan.As regards Asian talks, AB said in the placing RNS that they would be getting someone in to assess whether or not it was viable for a positive outcome to be achieved from legacy discussions. We were never told the outcome of that but given that she did tell us that Ebers and Vistagen looked fruitless then one would assume she would do the same for the Asian partner talks too.We should know very soon whether it was all BS or not. If the partner talks didn't collapse before AB came on board then chances are they've been in contact up to this point so if a deal is to be done then it could be almost ready.

[hollywood6] 25/11/2021 08:18

All in all its fantastic news today. Well done Anne and everyone involved. I think Anne will be missed. She seems very professional on the interviews that I have watched

[hollywood6] 25/11/2021 08:16

Do we know who was responsible for assessing if the Asian deal was still possible?

[hollywood6] 25/11/2021 08:15

So do you think AB was referring to the final durability study for Jan 22? Or did the results for the others come back earlier than anticipated?

[for fx sake] 25/11/2021 08:12

Things should hopefully turn around now.Lokks like there is nothing really in the way of stopping them finishing the phase 1 ready data package.I think Allenby said in their analysis that NXP002 would value the company at 9p per share with that alone, without any licensing deal (i.e as if they were going to market it themselves)We also have NXP004 data plus Oxilio deal.

[amaretto1] 25/11/2021 08:03

Very good news Ann is top draw ... Shes odviously happy to concur with data !!

[spurs90] 25/11/2021 07:10

Nuformix plc

("Nuformix" or the "Company")



Positive pre-clinical data on NXP002



Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, provides an update on its lead asset, NXP002, which it is currently developing as a potential novel treatment for Idiopathic Pulmonary Fibrosis ("IPF"). This update comes as a result of positive data received following initial pre-clinical studies.



NXP002 is a repurposed, new form of tranilast, that the Company is developing in an inhaled formulation for direct delivery to the lungs. Nuformix has successfully performed a number of pre-clinical studies as planned to generate a robust data package. The studies completed of the data package thus far comprise of:



- in vitro studies to demonstrate that NXP002 can be formulated in a formulation suitable for inhaled delivery by nebulisation; and

- in vivo studies to look at the pharmacokinetics and pharmacodynamics of NXP002 in a pre-clinical species when inhaled.



The in vitro studies demonstrated that it is feasible to formulate NXP002 into a simple and stable solution which has suitable properties for delivery via nebulisation. The data generated on these formulations also show that the drug can be efficiently delivered in the right particle size range for lung delivery using off-the-shelf and commonly used nebuliser devices. Thus, Nuformix believes that the delivery of NXP002 by nebulisation is feasible.



The first of the in vivo studies evaluated the pharmacokinetics of NXP002 when delivered by nebulisation to rats. This study demonstrated that NXP002 can be efficiently delivered to the lung, achieving significant drug levels, whilst limiting systemic exposure compared to oral dosing.

The second in vivo study evaluated the pharmacodynamics of NXP002 when delivered by nebulisation. This study showed that inhaled NXP002 could dose-dependently regulate the production of fibrosis-relevant mediators.



The final planned study as part of the NXP002 pre-clinical data package is an in vivo study investigating the durability of the pharmacodynamic effect. The Company anticipates receiving the data for this study in early 2022.



Dr Anne Brindley, CEO of Nuformix, said: "We're delighted with the positive readout of this data so far and it further cements our belief in NXP002 as a valuable asset. Tranilast is poorly soluble, meaning it is not well absorbed into the body and tissues, and it also has issues regarding systemic toxicity. NXP002 is a new form of tranilast that shows greater solubility than the original drug, allowing it to be delivered to the lungs that are the site of action for IPF. By delivering directly to the lungs, we anticipate that a lower dose will be required to produce a pharmacological and therapeutic effect with reduced systemic toxicity compared to oral dosing.



"We have previously reported data on the activity of NXP002 in human IPF lung slices in vitro, and the in vivo results to date are consistent with these data, both in terms of mediators modulated and the exposure required to achieve this modulation. The data generated to date provide a robust translational package and support the further progression of this asset. Further studies are ongoing to assess the durability of the pharmacodynamic effect and we look forward to updating the market in due course."